Roger Jeffs Sells 8,360 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,360 shares of the business’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $121,888.80. Following the sale, the chief executive officer now directly owns 826,985 shares in the company, valued at $12,057,441.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Roger Jeffs also recently made the following trade(s):

• On Monday, March 18th, Roger Jeffs sold 28,583 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total transaction of $452,183.06.

Liquidia Stock Down 0.4 %

Liquidia stock opened at $13.81 on Friday. Liquidia Co. has a 12-month low of $5.71 and a 12-month high of $16.99. The firm’s fifty day moving average is $14.75 and its 200 day moving average is $10.95. The company has a market capitalization of $1.05 billion, a PE ratio of -11.51 and a beta of 0.16.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The company had revenue of $4.53 million for the quarter, compared to analyst estimates of $5.29 million. Sell-side analysts expect that Liquidia Co. will post -1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of LQDA. Price T Rowe Associates Inc. MD raised its holdings in Liquidia by 9.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock worth $137,000 after buying an additional 989 shares during the last quarter. SkyView Investment Advisors LLC raised its holdings in Liquidia by 1.4% during the fourth quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company’s stock worth $1,342,000 after buying an additional 1,571 shares during the last quarter. BNP Paribas Arbitrage SNC raised its holdings in Liquidia by 20.5% during the first quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock worth $69,000 after buying an additional 1,702 shares during the last quarter. Chartwell Investment Partners LLC raised its holdings in Liquidia by 6.0% during the fourth quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company’s stock worth $197,000 after buying an additional 1,769 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Liquidia by 7.1% during the fourth quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company’s stock worth $178,000 after buying an additional 1,845 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of recent analyst reports. Wedbush restated an “underperform” rating and issued a $3.00 price target on shares of Liquidia in a research report on Thursday, December 21st. HC Wainwright boosted their price target on shares of Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Liquidia in a research report on Wednesday, April 10th. LADENBURG THALM/SH SH boosted their price target on shares of Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. Finally, Bank of America boosted their price target on shares of Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).